XML 31 R19.htm IDEA: XBRL DOCUMENT
v3.24.3

Business Segment Information (Notes) | 6 Months Ended
--- | ---
Sep. 30, 2024
Segment Reporting [Abstract] |
Business Segment Information | 11. Business Segment Information We operate and report our financial information in three reportable business segments: Healthcare, AST, and Life Sciences. Previously, we had four reportable business segments, however, as a result of the divestiture of our Dental segment, Dental is presented as discontinued operations. Historical information has been retrospectively adjusted to reflect these changes for comparability, as required. For more information, refer to Note 4 titled, "Discontinued Operations." Non-allocated operating costs that support the entire Company and items not indicative of operating trends are excluded from segment operating income. Our Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. Our products and services range from infection prevention consumables and capital equipment, as well as services to maintain that equipment; to the repair of re-usable procedural instruments; to outsourced instrument reprocessing services. In addition, our procedural solutions also include endoscopy accessories, instruments, and capital equipment infrastructure used primarily in operating rooms, ambulatory surgery centers, endoscopy suites, and other procedural areas. Our AST segment supports medical device and pharmaceutical manufacturers through a global network of contract sterilization and laboratory testing facilities, and integrated sterilization equipment and control systems. Our technology-neutral offering supports Customers every step of the way, from testing through sterilization. Our Life Sciences segment provides a comprehensive offering of products and services designed to support biopharmaceutical and medical device research and manufacturing facilities, in particular those focused on aseptic manufacturing. Our portfolio includes a full suite of capital equipment, consumable products, equipment maintenance and specialty services. We disclose a measure of segment income that is consistent with the way management operates and views the business. The accounting policies for reportable segments are the same as those for the consolidated Company. For the three and six months ended September 30, 2024 and 2023, revenues from a single Customer did not represent ten percent or more of the Healthcare, AST or Life Sciences segment revenues. Additional information regarding our segments is included in our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2024, which was filed with the SEC on May 29, 2024. Financial information for each of our segments is presented in the following table:
|  | Three Months Ended September 30, |  | Six Months Ended September 30,
|  | 2024 |  | 2023 |  | 2024 |  | 2023
Revenues: |  |  |  |  |  |  |  |
Healthcare |  | $ | 944,230 |  |  | $ | 870,056 |  |  | $ | 1,845,451 |  |  | $ | 1,688,930 |
AST |  | 256,737 |  |  | 235,053 |  |  | 506,540 |  |  | 468,152 |
Life Sciences |  | 127,945 |  |  | 133,095 |  |  | 256,423 |  |  | 264,508 |
Total revenues |  | $ | 1,328,912 |  |  | $ | 1,238,204 |  |  | $ | 2,608,414 |  |  | $ | 2,421,590 |
Operating income (loss): |  |  |  |  |  |  |  |
Healthcare |  | $ | 228,006 |  |  | $ | 204,054 |  |  | $ | 444,893 |  |  | $ | 402,236 |
AST |  | 109,902 |  |  | 110,783 |  |  | 227,616 |  |  | 220,373 |
Life Sciences |  | 53,700 |  |  | 50,284 |  |  | 106,284 |  |  | 100,125 |
Corporate |  | (97,129) |  |  | (87,020) |  |  | (198,877) |  |  | (178,893) |
Total operating income |  | $ | 294,479 |  |  | $ | 278,101 |  |  | $ | 579,916 |  |  | $ | 543,841 |
Less: Adjustments |  |  |  |  |  |  |  |
Amortization of acquired intangible assets (1) |  | $ | 67,971 |  |  | $ | 69,846 |  |  | $ | 135,632 |  |  | $ | 133,938 |
Acquisition and integration related charges (2) |  | 3,205 |  |  | 15,808 |  |  | 5,459 |  |  | 18,045 |
Tax restructuring (credits) costs (3) |  | (561) |  |  | — |  |  | (43) |  |  | 9 |
Amortization of inventory and property "step up" to fair value (1) |  | 1,402 |  |  | 917 |  |  | 2,793 |  |  | 2,539 |
Restructuring charges (credits) (4) |  | 2,796 |  |  | (23) |  |  | 30,878 |  |  | (4) |
Income from operations |  | $ | 219,666 |  |  | $ | 191,553 |  |  | $ | 405,197 |  |  | $ | 389,314 |
(1) For more information regarding our recent acquisitions and divestitures, refer to Note 3 titled, "Business Acquisitions and Divestitures." (2) Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions. (3) Costs incurred in tax restructuring. (4) For more information regarding our restructuring efforts, refer to Note 2 titled, "Restructuring." Additional information regarding our fiscal 2025 and fiscal 2024 revenue is disclosed in the following tables:
|  | Three Months Ended September 30, |  | Six Months Ended September 30,
|  | 2024 |  | 2023 |  | 2024 |  | 2023
Healthcare: |  |  |  |  |  |  |  |
Capital equipment |  | $ | 249,732 |  |  | $ | 254,905 |  |  | $ | 464,371 |  |  | $ | 493,004 |
Consumables |  | 341,707 |  |  | 306,025 |  |  | 685,061 |  |  | 586,306
Service |  | 352,791 |  |  | 309,126 |  |  | 696,019 |  |  | 609,620 |
Total Healthcare Revenues |  | $ | 944,230 |  |  | $ | 870,056 |  |  | $ | 1,845,451 |  |  | $ | 1,688,930 |
AST: |  |  |  |  |  |  |  |
Capital equipment |  | $ | 8,805 |  |  | $ | 1,754 |  |  | $ | 9,893 |  |  | $ | 2,628 |
Service |  | 247,932 |  |  | 233,299 |  |  | 496,647 |  |  | 465,524 |
Total AST Revenues |  | $ | 256,737 |  |  | $ | 235,053 |  |  | $ | 506,540 |  |  | $ | 468,152 |
Life Sciences: |  |  |  |  |  |  |  |
Capital equipment |  | $ | 23,012 |  |  | $ | 35,438 |  |  | $ | 49,488 |  |  | $ | 66,429 |
Consumables |  | 72,125 |  |  | 59,409 |  |  | 141,943 |  |  | 121,107 |
Service |  | 32,808 |  |  | 38,248 |  |  | 64,992 |  |  | 76,972 |
Total Life Sciences Revenues |  | $ | 127,945 |  |  | $ | 133,095 |  |  | $ | 256,423 |  |  | $ | 264,508 |
Total Revenues |  | $ | 1,328,912 |  |  | $ | 1,238,204 |  |  | $ | 2,608,414 |  |  | $ | 2,421,590 |
|  | Three Months Ended September 30, |  | Six Months Ended September 30,
|  | 2024 |  | 2023 |  | 2024 |  | 2023
Revenues: |  |  |  |  |  |  |  |
Ireland |  | $ | 22,802 |  |  | $ | 20,399 |  |  | $ | 44,996 |  |  | $ | 40,435 |
United States |  | 979,528 |  |  | 909,651 |  |  | 1,926,418 |  |  | 1,765,439 |
Other locations |  | 326,582 |  |  | 308,154 |  |  | 637,000 |  |  | 615,716 |
Total Revenues |  | $ | 1,328,912 |  |  | $ | 1,238,204 |  |  | $ | 2,608,414 |  |  | $ | 2,421,590 |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 10: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContent Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration